Trials / Completed
CompletedNCT02991118
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 779 (actual)
- Sponsor
- Esperion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bempedoic acid | bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided) |
| DRUG | placebo | Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided) |
Timeline
- Start date
- 2016-11-18
- Primary completion
- 2018-08-22
- Completion
- 2018-08-22
- First posted
- 2016-12-13
- Last updated
- 2020-04-27
- Results posted
- 2020-04-27
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02991118. Inclusion in this directory is not an endorsement.